90190
document
Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria : a controlled study . Gonadotropin-releasing hormone ( GnRH ) agonists have been shown to reduce symptoms of premenstrual syndrome ( PMS ) . This randomized , placebo-controlled study examined the efficacy of the GnRH agonist , leuprolide acetate depot , in a clearly defined PMS sample versus women with premenstrual symptoms in combination with dysphoric symptoms throughout the cycle , termed the premenstrual exacerbation ( PME ) group . Evaluation included the Structured Clinical Interview for DSM-III-R , administered in the follicular phase , and the subject Penn Dally Symptoms Report ( DSR ) maintained throughout the study . Thirty-three eligible women were randomized to double-blind treatment and administered 3.75 mg of depot leuprolide or a placebo once a month for 3 months . The subjects were seen for efficacy evaluations at the end of each cycle . Outcome measures were the DSRs and the 17-item Hamilton Depression Rating Scale ( HAM-D17 ) . The PMS leuprolide subjects improved significantly compared with the PMS placebo and PME leuprolide groups . The PME leuprolide group , who had dysphoric symptoms throughout the cycle , did not improve . Depression symptoms were at clinical levels premenstrually in the PMS and PME groups ; following treatment they remitted in the PMS group but not in the PME leuprolide subjects . Efficacy did not occur until after several months of leuprolide treatment , but there was no evidence that PMS symptoms worsened with the onset of treatment . These results replicate the findings in our preliminary open-label study . Leuprolide reduced PMS symptoms to minimal levels where symptoms were limited to the luteal phase . Leuprolide was not effective for women with ongoing dysphoric symptoms , suggesting that premenstrual depression may have mechanisms different from those of other dysphoric mood disorders .
90191
Intervention_Pharmacological
Gonadotropin-releasing hormone
90192
Intervention_Pharmacological
Gonadotropin-releasing hormone ( GnRH ) agonists
90193
Intervention_Pharmacological
GnRH agonist
90194
Intervention_Pharmacological
3.75 mg of depot leuprolide
90195
Intervention_Control
placebo
90196
Intervention_Pharmacological
leuprolide
90197
Intervention_Pharmacological
leuprolide
90198
Intervention_Pharmacological
leuprolide
90199
Intervention_Pharmacological
leuprolide
90200
Intervention_Pharmacological
Leuprolide
90201
Intervention_Pharmacological
Leuprolide
90202
Outcome_Physical
symptoms of premenstrual syndrome ( PMS ) .
90203
Outcome_Other
Structured Clinical Interview for DSM-III-R
90204
Outcome_Other
subject Penn Dally Symptoms Report ( DSR )
90205
Outcome_Other
efficacy
90206
Outcome_Other
DSRs
90207
Outcome_Other
17-item Hamilton Depression Rating Scale ( HAM-D17 )
90208
Outcome_Mental
dysphoric symptoms
90209
Outcome_Mental
Depression symptoms
90210
Outcome_Physical
PMS symptoms
90211
Outcome_Physical
PMS symptoms
90212
Participant_Condition
clearly defined PMS sample
90213
Participant_Condition
women with premenstrual symptoms in combination with dysphoric symptoms throughout the cycle ,
90214
Participant_Condition
premenstrual exacerbation ( PME )
90215
Participant_Sample-size
Thirty-three
90216
Participant_Sex
women